Of course a dolt like you knows far more than those who raised the price target to $11. Why do you waste your time? Do you actually believe anybody gives a S about you or your posts?
Sentiment: Strong Buy
I am always amazed how somebody like you gets on a computer and manages to use it. You are probably on the CVX and OXY boards posting that cold fusion has been perfected. One solution: IGNORE USER
The fact is, you are a sore loser who should not be in the market. You don't know how to lock in some profit during runs. You rode it down like a scared monkey clutching a banana falling from a tree. Now, you hang around like a penniless hobo. LOL
What happened to your "Dead Cat Bounce" claim? Oh, that's right. You just keep up your unreliable #$%$ as if you were not wrong. How about, "Oh Boy Did We Ever Get This One Wrong"?
6. 55 or 6.25 matters little if you are holding. If you are accumulating, it might be a positive. If you're scrounging for pennies and trying to scare small investors, karma is a #$%$.
The Street is the most overtly manipulative bag of nonsense out there. This dead cat bounce "headline" gives them wide notice on the web. It matters little if it turns out to be accurate on an individual stock or historically for everything they publish. They are no better than horoscopes that predict wealth or loss of it. Once in awhile, odds say the will be right and then they can talk about that.
I don't dispute what you have said. If I did, I still would not own GALE. However, in spite of all of the Cramer and Feurstein and short trading nonsense, the questions I posed remain to be answered.
I certainly respect your insight and am no fan of frivolous litigation. If can agree that the following happened, then an investigation of the facts (a lawsuit only depending upon the outcome of the investigation) is in order.
1. GALE management hired a firm to promote GALE in forums such as Seeking Alpha;
2. GALE management failed to disclose number 1 to shareholders; and,
3. GALE management was unloading large amounts of stock as the share price rose.
The questions to be answered:
1. Was the retention of the firm a material event that should have been fully disclosed to shareholders?
2. Was the manner in which the firm marketed improper and was GALE management knowledgeable?
3. Did/Do GALE management have material information regarding GALE (Abstral sales, Neuvax trials) that may negatively impact the share price that they failed to disclose while themselves selling?
If the answers to these three questions are no, then no problem and any lawsuit filed should be a waste of the paper. If the answers to one or more (and particularly all three) are yes, we have a significant problem.
Very unlikely. Let's face the facts here. Anyone who has been around for a year or more knows that I have been pro-GALE. I still own it. That said, law firms come out of the woodwork to "investigate" biotechs that undergo trial or NDA failures and undergo big shareprice drops to see if management was pumping while selling, failing to disclose material facts. Here, there is apparently evidence that GALE management retained an organization to promote GALE and as the shareprice rose while management was unloading stock. To me, the question is why. Was management selling unrelated to anything they know about Abystral sales, Neuvax trials, or anything else happening that may negatively impact the share price? Was the retention marketing plan a material event and should it have been disclosed? If not, no big deal IMO. If so, people should be stripped of their illicit gains and face prosecution.
This WAS a great thread - for identifying a whole series of Ignore User candidates.
Everyone has their limits, risk tolerance and available finance. Folks shouldn't laugh at people playing the penny slots, so I guess it's not right to laugh at you.
LOS ANGELES, CA, Feb 14, 2014 (Marketwired via COMTEX) -- Decision Diagnostics Corp. (otcqb:DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's LifeScan Ultra family of glucose testing meters, today announced that that the Company has executed a Terms Agreement with a major east coast based litigation prosecution fund for the financing of the prosecution of DECN's countersuits brought against LifeScan, Inc., a division of Johnson and Johnson, Inc. DECN has asserted claims for anti-trust violations and false advertising.
"The antitrust prosecution, if successful, carries with it a possible award of triple damages," said Keith Berman, DECN's Principal Executive Officer and the GenStrip Program Director. Mr. Berman further observed, "In our case, we are pursuing two prizes simultaneously, first the prosecution of our anti-trust and false advertising claims for J&J's anti-competitive behavior throughout our dispute, and secondly, we will assemble our arguments and begin a process of collecting on the damages we have suffered as the result of the J&J patent litigation on which the Court of Appeals for the Federal Circuit has ruled favorably for DECN. This higher court ruling offers DECN an opportunity to begin prosecution efforts, an upcoming attack as some have called it, on the $12.7 million court ordered litigation bond. Our litigation financing partner has put up a substantial pool of capital specifically to assist us in achieving significant positive outcomes for these prosecutions."
In the meantime, the company reminds shareholders and all interested parties that it is currently airing its GenStrip commercial video titled, "A Winter Patchwork" in every region of the country, and has secured play times on all cable outlets that will televise the 2014 Winter Olympics. The company's media schedule calls for alm
Sentiment: Strong Buy